Literature DB >> 8452418

DNA ploidy pattern of each carcinomatous component in adenosquamous lung carcinoma.

Y Ichinose1, N Hara, S Takamori, K Maeda, T Yano, M Ohta.   

Abstract

The relationship between adenocarcinomatous and squamous carcinomatous components in 12 surgically resected adenosquamous lung carcinomas was analyzed using DNA flow cytometry. Well-preserved parts of the tumor showing either adenocarcinoma or squamous cell carcinoma were identified on paraffin blocks. The cells obtained from each component were stained with propidium iodide for DNA flow cytometry. In the analysis of DNA flow cytometry, both components in the same tumor were defined as being related to each other when they showed diploidy or when at least one DNA index of abnormal clones between two aneuploid components was identical. According to these criteria, 8 (67%) of the 12 tumors showed a relationship between adenocarcinomatous and squamous carcinomatous components. This suggests that, despite the different phenotypes, both components of some adenosquamous lung carcinomas may share similar biological characteristics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452418     DOI: 10.1016/0003-4975(93)90257-i

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.

Authors:  Hidetaka Uramoto; Sohsuke Yamada; Takeshi Hanagiri
Journal:  J Cardiothorac Surg       Date:  2010-10-29       Impact factor: 1.637

Review 2.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

3.  Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.

Authors:  Shaomin Yu; Zhihong Zhang; Bin Zhang; Yongqian Shu; Hao Wu; Xiang Huang; Qianqian Yu; Renhua Guo
Journal:  Med Oncol       Date:  2014-05-17       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.